64 related articles for article (PubMed ID: 17979781)
1. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs.
MacNeil DJ
Curr Top Med Chem; 2007; 7(17):1721-33. PubMed ID: 17979781
[TBL] [Abstract][Full Text] [Related]
2. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice.
Kushi A; Sasai H; Koizumi H; Takeda N; Yokoyama M; Nakamura M
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15659-64. PubMed ID: 9861026
[TBL] [Abstract][Full Text] [Related]
3. Modulation of neuropeptide Y receptors for the treatment of obesity.
Sato N; Ogino Y; Mashiko S; Ando M
Expert Opin Ther Pat; 2009 Oct; 19(10):1401-15. PubMed ID: 19743896
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs. Current Status.
Moreno-Herrera A; García A; Palos I; Rivera G
Mini Rev Med Chem; 2014 Oct; ():. PubMed ID: 25355591
[TBL] [Abstract][Full Text] [Related]
5. Regulation of energy homeostasis by the NPY system.
Loh K; Herzog H; Shi YC
Trends Endocrinol Metab; 2015 Mar; 26(3):125-35. PubMed ID: 25662369
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of neuropeptide Y (NPY) receptor ligands.
Brothers SP; Wahlestedt C
EMBO Mol Med; 2010 Nov; 2(11):429-39. PubMed ID: 20972986
[TBL] [Abstract][Full Text] [Related]
7. Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions.
Shende P; Desai D
Adv Exp Med Biol; 2020; 1237():37-47. PubMed ID: 31468359
[TBL] [Abstract][Full Text] [Related]
8. The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-brain Axis.
Wu Y; He H; Cheng Z; Bai Y; Ma X
Curr Protein Pept Sci; 2019; 20(7):750-758. PubMed ID: 30678628
[TBL] [Abstract][Full Text] [Related]
9. Amygdala NPY Circuits Promote the Development of Accelerated Obesity under Chronic Stress Conditions.
Ip CK; Zhang L; Farzi A; Qi Y; Clarke I; Reed F; Shi YC; Enriquez R; Dayas C; Graham B; Begg D; Brüning JC; Lee NJ; Hernandez-Sanchez D; Gopalasingam G; Koller J; Tasan R; Sperk G; Herzog H
Cell Metab; 2019 Jul; 30(1):111-128.e6. PubMed ID: 31031093
[TBL] [Abstract][Full Text] [Related]
10. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
Kühnen P; Krude H; Biebermann H
Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
[TBL] [Abstract][Full Text] [Related]
11. Y1 and Y5 receptors are both required for the regulation of food intake and energy homeostasis in mice.
Nguyen AD; Mitchell NF; Lin S; Macia L; Yulyaningsih E; Baldock PA; Enriquez RF; Zhang L; Shi YC; Zolotukhin S; Herzog H; Sainsbury A
PLoS One; 2012; 7(6):e40191. PubMed ID: 22768253
[TBL] [Abstract][Full Text] [Related]
12. The role of NPY in hypothalamic mediated food intake.
Mercer RE; Chee MJ; Colmers WF
Front Neuroendocrinol; 2011 Oct; 32(4):398-415. PubMed ID: 21726573
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor.
Pedrazzini T; Seydoux J; Künstner P; Aubert JF; Grouzmann E; Beermann F; Brunner HR
Nat Med; 1998 Jun; 4(6):722-6. PubMed ID: 9623984
[TBL] [Abstract][Full Text] [Related]
14. Peripheral-specific Y1 receptor antagonism increases thermogenesis and protects against diet-induced obesity.
Yan C; Zeng T; Lee K; Nobis M; Loh K; Gou L; Xia Z; Gao Z; Bensellam M; Hughes W; Lau J; Zhang L; Ip CK; Enriquez R; Gao H; Wang QP; Wu Q; Haigh JJ; Laybutt DR; Timpson P; Herzog H; Shi YC
Nat Commun; 2021 May; 12(1):2622. PubMed ID: 33976180
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
[TBL] [Abstract][Full Text] [Related]
16. NPY and NPY receptors in the central control of feeding and interactions with CART and MC4R in Siberian sturgeon.
Yuan D; Gao Y; Zhang X; Wang B; Chen H; Wu Y; Chen D; Wang Z; Li Z
Gen Comp Endocrinol; 2019 Dec; 284():113239. PubMed ID: 31394086
[TBL] [Abstract][Full Text] [Related]
17. Modified Peptide YY Molecule Attenuates the Activity of NPY/AgRP Neurons and Reduces Food Intake in Male Mice.
Jones ES; Nunn N; Chambers AP; Østergaard S; Wulff BS; Luckman SM
Endocrinology; 2019 Nov; 160(11):2737-2747. PubMed ID: 31074796
[TBL] [Abstract][Full Text] [Related]
18. The melanocortin pathway and control of appetite-progress and therapeutic implications.
Baldini G; Phelan KD
J Endocrinol; 2019 Apr; 241(1):R1-R33. PubMed ID: 30812013
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
